Abstract
Aim
People with serious mental illness (SMI) are at an increased risk for suicide. Social approach and avoidance motivations are linked to social functioning, and social isolation is a risk factor for suicide. This study uses ecological momentary assessment (EMA) to understand social approach and avoidance motivations in relation to symptoms and suicidal ideation (SI).
Methods
Participants (N = 128) diagnosed with schizophrenia, schizoaffective disorder, or a mood disorder with psychotic features completed assessments of SI and symptoms at baseline. They completed EMA surveys 3×/day for 10 days. EMA surveys included questions about approach and avoidance motivations and psychotic symptoms. Participants were split into four groups based on the median scores of approach and avoidance.
Results
Participants with SI at baseline had higher mean social avoidance motivation, t(126) = 2.84, p = .003, and lower mean social approach motivation, t(126) = −2.44, p = .008, than participants without baseline SI. Greater baseline positive symptoms were related to greater mean avoidance, r = .231, p = .009, but not approach motivation. The low approach/high avoidance group had significantly higher current SI than those with high approach/low avoidance (p < .001). Overall, the low approach/high avoidance group reported more EMA-measured voices than the low approach/low avoidance group (p < .001) and the high approach/low avoidance group (p < .001). Similarly, the low approach/high avoidance group reported more EMA-measured suspiciousness than the low approach/low avoidance (p < .001) and the high approach/low avoidance groups (p < .001).
Conclusion
The results of this study point to the role of social approach and avoidance motivations in relation to SI and psychotic symptoms. Clinically, exposure therapies and cognitive behavioral therapies may help to address these social approach and avoidance processes linked to SI.
ACKNOWLEDGEMENTS
We would like to thank Katelyn Barone, Bianca Tercero, Cassi Springfield, Linlin Fan, Ian Kilpatrick, Snigdha Kamarsu, Tess Filip, Avery Quynh, Vanessa Scott, and Maxine Hernandez for their involvement in data collection and recruitment.
DISCLOSURE STATEMENT
R.C.M. is a co-founder of KeyWise AI, Inc. and a consultant for NeuroUX. The terms of this arrangement have been reviewed and approved by UC San Diego in accordance with its conflict of interest policies. P.D.H. has received consulting fees or travel reimbursements from Alkermes, Bio Excel, Boehringer Ingelheim, Karuna Pharma, Merck Pharma, Minerva Pharma, SK Pharma, and Sunovion (DSP) Pharma in the past year. He receives royalties from the Brief Assessment of Cognition in Schizophrenia (owned by WCG Verasci, Inc. and contained in the MATRICS Consensus Cognitive Battery). He is chief scientific officer of i-Function, Inc.
Additional information
Funding
Notes on contributors
Emma M. Parrish
Emma M. Parrish, MS, San Diego State University/University of California San Diego Joint Doctoral Program in Clinical Psychology, San Diego, California, USA.
Samantha Chalker
Samantha Chalker, PhD, University of California San Diego Department of Psychiatry, San Diego, California, USA; Veterans Affairs San Diego Healthcare System, San Diego, California, USA.
Mayra Cano
Mayra Cano, BS, University of California San Diego Department of Psychiatry, San Diego, California, USA; University of Pittsburgh School of Nursing, Pittsburgh, Pennsylvania, USA.
Philip D. Harvey
Philip D. Harvey, PhD, University of Miami Miller School of Medicine, Miami, Florida, USA; Research Service Miami VA Medical Center, Miami, Florida, USA.
Charles T. Taylor
Charles T. Taylor, PhD, University of California San Diego Department of Psychiatry, San Diego, California, USA.
Amy Pinkham
Amy Pinkham, PhD, The University of Texas at Dallas, Richardson, TX, USA.
Raeanne C. Moore
Raeanne C. Moore, PhD, University of California San Diego Department of Psychiatry, San Diego, California, USA.
Robert A. Ackerman
Robert A. Ackerman, PhD, The University of Texas at Dallas, Richardson, TX, USA.
Colin A. Depp
Colin A. Depp, PhD, University of California San Diego Department of Psychiatry, San Diego, California, USA; Veterans Affairs San Diego Healthcare System, San Diego, California, USA.